Patents by Inventor Alexander L. Ruchelman

Alexander L. Ruchelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl compounds useful as MK2 inhibitors
    Patent number: 11760763
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: September 19, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jian Guo, John Malona, Alexander L. Ruchelman, Sekhar S. Surapaneni
  • MK2 inhibitors, synthesis thereof, and intermediates thereto
    Patent number: 11655257
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: May 23, 2023
    Assignee: Celgene CAR LLC
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • Forms and compositions of a MK2 inhibitor
    Patent number: 11629153
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: April 18, 2023
    Assignee: Celgene CAR LLC
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20220411402
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Application
    Filed: July 18, 2022
    Publication date: December 29, 2022
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • MK2 INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20220259222
    Abstract: The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 18, 2022
    Inventors: Alexander L. Ruchelman, John R. Coombs, Keming Zhu, Daniel Lim, Candice Lee Joe, David T. George, Bin Zheng, Dong Lin
  • Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
    Patent number: 11414399
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 16, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • HETEROARYL COMPOUNDS USEFUL AS MK2 INHIBITORS
    Publication number: 20220064183
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 3, 2022
    Inventors: Jian Guo, John Malona, Alexander L. Ruchelman, Sekhar S. Surapaneni
  • Heteroaryl compounds useful as MK2 inhibitors
    Patent number: 11124525
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 21, 2021
    Assignee: Celgene CAR LLC
    Inventors: Jian Guo, John Malona, Alexander L. Ruchelman, Sekhar S. Surapaneni
  • 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5?,6?:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
    Patent number: 11098057
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene CAR LLC
    Inventors: John Malona, Alexander L. Ruchelman
  • FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
    Publication number: 20210198276
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 29, 2020
    Publication date: July 1, 2021
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20210139501
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 13, 2021
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, JR., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • MK2 inhibitors, synthesis thereof, and intermediates thereto
    Patent number: 10894796
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 19, 2021
    Assignee: Celgene CAR LLC
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • Forms and compositions of a MK2 inhibitor
    Patent number: 10882867
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 5, 2021
    Assignee: Celgene CAR LLC
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20200231567
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 23, 2020
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
    Patent number: 10669257
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 2, 2020
    Assignee: Celgene Corporation
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
    Publication number: 20200148701
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 15, 2018
    Publication date: May 14, 2020
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou
  • HETEROARYL COMPOUNDS USEFUL AS MK2 INHIBITORS
    Publication number: 20200102325
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 15, 2018
    Publication date: April 2, 2020
    Inventors: Jian Guo, John Malona, Alexander L. Ruchelman, Sekhar S. Surapaneni
  • MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20200102326
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Application
    Filed: March 15, 2018
    Publication date: April 2, 2020
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, JR., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • 9,10,11,12-TETRAHYDRO-8H-[1,4]DIAZEPINO[5',6':4,5]THIENO[3,2-F]QUINOLIN-8-ONE COMPOUNDS AND USES THEREOF
    Publication number: 20200102327
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 15, 2018
    Publication date: April 2, 2020
    Inventors: John Malona, Alexander L. Ruchelman
  • 3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
    Patent number: 10434095
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, e.g., 3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione, or an isotopologue thereof, or an enantiomer or a mixture of enantiomers thereof. Pharmaceutical compositions comprising and methods for using the compounds are also disclosed.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: October 8, 2019
    Assignee: Celgene Corporation
    Inventors: Hon-wah Man, Alexander L. Ruchelman